{"id":616305,"title":"Notice to stakeholders: Health Canada's expectations regarding risk-management measures for clinical trials involving psychedelic-assisted psychotherapy - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-03-02","captureTimestamp":"2026-03-02T19:10:32.961000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/expectations-risk-management-measures-clinical-trials-psychedelic-assisted-psychotherapy.html","snippet":"Notice to stakeholders: Health Canada's expectations regarding risk-management measures for clinical trials involving psychedelic-assisted psychotherapy December 5, 2022 Our file number: 22-111811-471 Purpose Health Canada recognizes the growing interest in the use of…","rawSnapshotUrl":"/api/snapshots/raw/616305","browseUrl":"https://replay.healtharchive.ca/job-6/20260302191032/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/expectations-risk-management-measures-clinical-trials-psychedelic-assisted-psychotherapy.html#ha_snapshot=616305","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}